Drs. Owens and Rosmarin discuss an overview of the TRuE-V studies and unmet needs in vitiligo.
Results and Implications From the Open-Label Arm of the TRuE-V Long-Term Extension Phase 3 Study
The key safety and efficacy data of the TRuE-V studies are discussed.
The study design for the TRuE-V long-term extension study is discussed.
Dr. Rosmarin discusses the efficacy data from the TRuE-V long-term extension study.
Key adverse events from the TRuE-V studies are highlighted.
The limitations from the TRuE-V studies are analyzed.
Drs. Owens and Rosmarin discuss payer and provider perspectives from the TRuE-V studies.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Fenebrutinib trials show success in treating both relapsing and progressive multiple sclerosis
2
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
3
Fecal Transplants with Immunotherapy Extend Survival in Advanced Melanoma Patients
4
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
5
